跳转至内容
Merck
CN

Y0001171

黄芪甲苷IV

European Pharmacopoeia (EP) Reference Standard

登录 查看组织和合同定价。

选择尺寸

关于此项目

经验公式（希尔记法）:
C41H68O14
化学文摘社编号:
84687-43-4
分子量:
784.97
NACRES:
NA.24
PubChem Substance ID:
329831290
UNSPSC Code:
41116107
MDL number:
MFCD16036240

主要文件

查看所有文档
技术服务
需要帮助？我们经验丰富的科学家团队随时乐意为您服务。
让我们为您提供帮助
技术服务
需要帮助？我们经验丰富的科学家团队随时乐意为您服务。
让我们为您提供帮助

产品名称

黄芪甲苷IV, European Pharmacopoeia (EP) Reference Standard

InChI

1S/C41H68O14/c1-35(2)24(54-33-29(48)26(45)20(44)17-51-33)9-11-41-18-40(41)13-12-37(5)31(39(7)10-8-25(55-39)36(3,4)50)19(43)15-38(37,6)23(40)14-21(32(35)41)52-34-30(49)28(47)27(46)22(16-42)53-34/h19-34,42-50H,8-18H2,1-7H3/t19-,20+,21-,22+,23-,24-,25-,26-,27+,28-,29+,30+,31-,32-,33-,34+,37+,38-,39+,40-,41+/m0/s1

SMILES string

CC(C)(O)[C@@H]1CC[C@@](C)(O1)[C@H]2[C@@H](O)C[C@@]3(C)[C@@H]4C[C@H](O[C@@H]5O[C@H](CO)[C@@H](O)[C@H](O)[C@H]5O)[C@H]6C(C)(C)[C@H](CC[C@@]67C[C@@]47CC[C@]23C)O[C@@H]8OC[C@@H](O)[C@H](O)[C@H]8O

InChI key

QMNWISYXSJWHRY-YLNUDOOFSA-N

grade

pharmaceutical primary standard

API family

astragaloside

manufacturer/tradename

EDQM

mp

295-296 °C (lit.)

application(s)

pharmaceutical (small molecule)

format

neat

正在寻找类似产品? 访问 产品对比指南

相关类别

Application

黄芪甲苷IVEP参考标准品的预期用途是欧洲药典规定的实验室测试。

Biochem/physiol Actions

抗炎。

General description

本品按现行药典规定交付。所有本产品相关的支持信息，包括SDS和任何产品信息宣传册，均是在药典的授权下制定和发布的。
如需进一步信息和支持，请访问现行药典网站。

Other Notes

可能适用相应的销售限制。

Packaging

本品按照现行药典要求提供。有关当前单位数量，请见EDQM 参考目录。

存储类别

11 - Combustible Solids

wgk

WGK 3

flash_point_f

Not applicable

flash_point_c

Not applicable

历史批次信息供参考:

分析证书(COA)

Lot/Batch Number

It looks like we've run into a problem, but you can still download Certificates of Analysis from our 文件 section.

如需帮助，请联系 客户支持

已有该产品？

在文件库中查找您最近购买产品的文档。

访问文档库

Feng Liu et al.
Archivum immunologiae et therapiae experimentalis, 68(6), 33-33 (2020-10-24)
Astragaloside IV (AS-IV) has shown anti-tumorigenic properties in certain cancers for its effect of boosting the body's immune system, but its role in colorectal cancer (CRC) remains unclear. In this study, we investigated the therapeutic effect of AS-IV in CRC
Jing Zhang et al.
FEMS microbiology letters, 367(4) (2020-02-29)
Excessive secretion of inflammatory factors (cytokine storm) plays a significant role in H1N1-induced acute pneumonia, and autophagy acts as a cell-intrinsic mechanism to regulate inflammation. Astragaloside IV (AS-IV), originating from the astragalus root, possesses multiple pharmacological activities, such as anti-inflammation.
Shuang Ren et al.
Journal of traditional Chinese medicine = Chung i tsa chih ying wen pan, 33(3), 413-416 (2013-09-13)
To review the pharmacological effects and mechanisms of action of Astragaloside IV in Huangqi (Radix Astragali Mongolici). Aticles focusing on Astragaloside IV in English and Chinese in databases were collected and reviewed in order to summarize the latest extraction separation
Biwang Liu et al.
Pharmacology, 105(1-2), 90-101 (2019-09-26)
Astragaloside IV has shown its promising effect on acute respiratory distress syndrome (ARDS). We aim to explore whether astragaloside IV is effective for ARDS treatment in a lipopolysaccharides (LPS)-induced cell model and whether autophagy is involved in the therapeutic function
Li Wang et al.
Experimental biology and medicine (Maywood, N.J.), 239(10), 1310-1324 (2014-06-01)
Astragaloside IV (AS-IV) is a major active ingredient from Radix astragali, which has been considered as a renoprotective agent; however, its molecular mechanisms are unclear. Thus, we designed to investigate the renoprotective effects and mechanisms of AS-IV in rat model

我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.

联系客户支持